It happened on a podcast, as most things do now. On February 27, 2026, US Health and Human Services Secretary Robert F. Kennedy Jr. sat down with Joe Rogan and dropped one of the biggest announcements in the history of functional wellness: roughly 14 of the 19 peptides the FDA had effectively banned from compounding pharmacies were coming back. Legal. Accessible. From what RFK called "ethical suppliers."
The biohacking world lost its mind. Dave Asprey called it a win for the people. Clinics started updating their menus. Stock in Hims and Hers surged. And Australians opened their phones, watched the discourse unfold, and quietly wondered: does any of this apply to us?
The short answer is no. Not yet. Possibly not for a long time. But the conversation still matters, and here is why.
What RFK Jr Actually Said and What It Does and Doesn't Change
The announcement came during episode #2461 of the Joe Rogan Experience. Kennedy stated that the FDA would, within weeks, move approximately 14 of 19 peptides from Category 2 status (the "do not compound" list) back to Category 1, which allows licensed compounding pharmacies to prepare them under a physician's prescription. The full Category 2 list includes: BPC-157, Cathelicidin LL-37, Emideltide (DSIP), Epitalon, GHK-Cu (injectable), GHRP-2, GHRP-6, Ipamorelin acetate, Kisspeptin-10, KPV, Melanotan II, PEG-MGF, MOTS-C, Semax, Thymosin Beta-4 fragment (LKKTETQ), AOD-9604, CJC-1295, Selank acetate, and Thymosin Alpha-1.
Industry analysts suggest the five most likely to remain restricted are those with the weakest safety data or strongest adverse event signals: Melanotan II, GHRP-2, Cathelicidin LL-37, Ipamorelin, and potentially GHRP-6.
Kennedy's argument: the original FDA ban, issued in late 2023 under the Biden administration, restricted these peptides not because of proven harm but largely because they lacked formal FDA approval. He also flagged a real-world consequence that compounding pharmacy advocates have been making for years. By restricting access through legitimate medical channels, the FDA pushed users directly into the grey market, where product quality, dosing accuracy, and contamination risks are entirely unregulated.
It is worth noting what this reversal does not do. It does not mean these peptides are FDA approved. It does not mean anyone can walk into a pharmacy and ask for BPC-157 off the shelf. It means that licensed compounding pharmacies can prepare them legally for individual patients under physician prescription. Physician oversight, labs, and informed consent are all still required.
As of the time of writing, no formal FDA rule change has been filed. No Federal Register notice has been issued. The announcement was a signal of intent, not a completed regulatory action. The formal decision is expected within weeks.
Now, About Australia. Are We Ahead or Behind?
Behind. Meaningfully so. And the gap is widening.
In Australia, most therapeutic peptides are classified as Schedule 4 prescription-only medicines under the Therapeutic Goods Administration's Poisons Standard. That includes BPC-157, TB-500, CJC-1295, GHRP-2, GHRP-6, and most growth hormone secretagogues. Melanotan II goes further. It is a prohibited import, subject to TGA enforcement and seizure at customs.
BPC-157, arguably the most talked about peptide in functional health circles globally, was formally moved to Schedule 4 by the TGA in June 2024. That is the same year the US was just beginning its own restriction fight. The TGA's position: limited human clinical trial data, high misuse potential in athletic and anti-ageing markets, and insufficient evidence to support the therapeutic claims being made online. Sport Integrity Australia lists it as an S0 non-approved substance, prohibited at all times for athletes.
The TGA does offer pathways. Doctors can prescribe peptides through the Special Access Scheme (SAS) or via the Authorised Prescriber pathway, even for compounds without formal TGA approval. This has created a legitimate, physician-supervised peptide therapy sector in Australia. Clinics like BioV8, Everlab, VitaHealth, and Tides Peptides are operating in this space, providing access through proper medical channels for patients with documented clinical need.
But here is the tension: the bar for medical justification is real. The TGA monitors prescribing patterns closely. Practitioners have faced tribunal proceedings and suspensions for prescribing peptides without adequate clinical rationale. "I want to optimise my recovery" is not, by itself, sufficient.
What the TGA Will and Won't Let Us Say
This is where it gets nuanced for anyone publishing in the Australian wellness space.
The TGA regulates not just the substances themselves but the claims made about them. Under the Therapeutic Goods Act 1989 and the Therapeutic Goods Advertising Code, it is illegal to make therapeutic claims about unapproved goods to Australian consumers. That means any editorial or brand content cannot claim that BPC-157 heals leaky gut, that AOD-9604 burns fat, or that Thymosin Alpha-1 boosts immunity, even if those are the exact reasons people are using them.
What this means practically for media and the clinics: we can discuss the regulatory landscape, the research context, and what is happening globally. We can cover what these peptides are and what the science says without making direct therapeutic claims. We can point readers toward licensed practitioners. What we cannot do is tell someone to use a specific peptide for a specific outcome.
The grey market, where "research chemical" suppliers sell peptides labelled "not for human use," remains active in Australia, but the legal exposure for both buyers and sellers has increased. A Victorian resident was recently fined for importing unapproved peptides without permission. Penalties in Queensland reach up to $32,260 for possession without a valid prescription.
What This Means for the Australian Longevity Scene
The RFK Jr announcement matters to Australian wellness even if it changes nothing here immediately. It signals a global direction of travel. The US, which has historically set the pace for functional medicine adoption, is moving toward supervised access rather than prohibition. If that regulatory model proves viable, quality controlled and physician supervised with reduced black market activity, it strengthens the case for advocates pushing the TGA to expand its own pathways.
The Australian longevity clinic sector is already making that argument. Clinics operating through SAS and Authorised Prescriber frameworks are building the evidence base for what supervised access looks like locally. The stronger that track record, the more credible the push for expanded access becomes.
For now, if you are in Australia and you are interested in peptide therapy, the path is clear: find a practitioner who operates within TGA frameworks, go through a proper clinical assessment, and do not import anything without understanding the legal exposure. The grey market is not worth it. With the global conversation shifting toward quality and oversight, the legitimate pathway is only going to get better.
Explore Peptide Therapy in Australia
Looking for a clinic that operates within TGA guidelines? These are worth knowing:
- BioV8Â biov8.com.au
- Everlab everlab.com
- VitaHealth vitahealth.com.au
- Tides Peptides tides.health
Related Reads
Gym Membership Cancellation Law Australia
Serena Williams Ozempic Weight Loss Deal
BioHax publishes health and wellness information for educational purposes only. Nothing in this article constitutes medical advice. Peptide therapy must be accessed through a registered Australian medical practitioner operating within TGA regulations. Do not purchase or use peptides without a valid prescription from a licensed healthcare provider.
Â
